Research and Markets: Pulmonary Arterial Hypertension Pipeline Insights 2015 – Provides a Pulmonary Arterial Hypertension Landscape across the Globe

DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/dvb9jt/pulmonary)
has announced the addition of the “Pulmonary
Arterial Hypertension-Pipeline Insights”
report to their
offering.

Pulmonary Arterial Hypertension- Pipeline Insights provides the in-depth
analysis of the pipeline assets across the Pulmonary Arterial
Hypertension. The main objective of this report to track competitor
pipeline molecules, related research activities, technology,
collaborations, in-licensing and out-licensing deals. The Pulmonary
Arterial Hypertension Report helps to identify emerging players with
potentially strong product information and create effective
counter-strategies to gain competitive advantage.

Pulmonary Arterial Hypertension- Pipeline Insights Report covers the
Pulmonary Arterial Hypertension pipeline molecules at various stages of
development like Pre-registration phase, clinical phases (Phase III,
Phase II & Phase I), pre-clinical and discovery phases. The Report also
provides Pulmonary Arterial Hypertension related therapeutic assessments
by molecule type, route of administration, monotherapy and combination
products.

Scope

  • The report provides a Pulmonary Arterial Hypertension Landscape across
    the globe
  • The report provides drug profiles which includes product description,
    MOA, licensors & collaborators, technology, development partner and
    chemical information
  • Coverage of the Pulmonary Arterial Hypertension pipeline on the basis
    of target, MOA, route of administration, technology involved and
    molecule type
  • The report reviews key players involved in the therapeutics
    development for Pulmonary Arterial Hypertension and also provide
    company profiling

Key Topics Covered:

  • Pulmonary Arterial Hypertension Overview
  • Pulmonary Arterial Hypertension Pipeline Therapeutics
  • Pulmonary Arterial Hypertension Therapeutics under Development by
    Companies
  • Pulmonary Arterial Hypertension Late Stage Products (Filed and Phase
    III)
  • Comparative Analysis
  • Pulmonary Arterial Hypertension Mid Clinical Stage Products (Phase II)
  • Comparative Analysis
  • Pulmonary Arterial Hypertension Early Clinical Stage Products (Phase I
    and IND Filed)
  • Comparative Analysis
  • Pulmonary Arterial Hypertension Discovery and Pre-Clinical Stage
    Products
  • Comparative Analysis
  • Drug Candidate Profiles
  • Pulmonary Arterial Hypertension – Therapeutics Assessment
  • Assessment by Monotherapy Products
  • Assessment by Combination Products
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Pulmonary Arterial Hypertension – Discontinued Products
  • Pulmonary Arterial Hypertension – Dormant Products
  • Companies Involved in Therapeutics Development for Pulmonary Arterial
    Hypertension

For more information visit http://www.researchandmarkets.com/research/dvb9jt/pulmonary

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Powered by WPeMatico